Serum Institute of India: 1 crore doses of Quadrivalent Human Papillomavirus vaccine by December 2022

Serum Institute tells Centre it can supply 1 crore doses of its indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer, by December 2022

Advertisement

According to government sources, the Serum Institute of India has notified the Center that it can provide 1 crore doses of its indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer by December 2022.

In a letter to the Union health ministry, Prakash Kumar Singh, Director, Government and Regulatory Affairs, Serum Institute of India (SII), confirmed the supply of 1 crore doses of qHPV by December 2022 for the National Vaccination Program.

Singh stated in his letter that SII will provide the vaccination at a reasonable price. He also mentioned that the price cannot be disclosed before the online tendering process begins.

The Cure: Quadrivalent Human Papillomavirus vaccine

On July 12, SII acquired market authorization from the Drugs Controller General of India (DCGI) to manufacture qHPV.

The phase 2/3 clinical trial of the vaccine has been completed with the support of the Department of Biotechnology.

It has recently been reported that the government advisory council NTAGI has also approved the qHPV vaccination after analysing the results of the vaccine’s clinical trials.

The qHPV vaccine CERVAVAC has shown a significant antibody response that is almost 1,000 times higher than the baseline against all targeted HPV types and in all dose and age categories, according to Singh’s statement in the application to DCGI.

Cervical Cancer history in India

According to the letter, thousands of women are diagnosed with cervical cancer each year, along with a few other cancers, and the death rate is also very high.

In India, cervical cancer is the second most common malignancy among women between the ages of 15 and 44. Also noteworthy is the fact that the nation is currently completely dependent on foreign manufacturers for the HPV vaccine.

Singh claimed in the application, “According to our group’s ideology and under the direction of our CEO, Dr Adar C. Poonawalla, it has always been our goal to provide high-quality “Made in India” vaccines for the people of our nation and the rest of the globe at reasonable prices.”